Cremophor EL-containing paclitaxel-induced anaphylaxis: A call to action

Community Oncology

Volumn 6, Issue 3, 2009, Pages 132-134

  Irizarry, Lauren D ^a,b   Thanh, Ha Luu ^a,b   McKoy, June M ^a   Samaras, Athena T ^a,b   Fisher, Matthew J ^a,b   Carias, Edson E ^a,b   Raisch, Dennis W ^c   Calhoun, Elizabeth A ^d   Bennett, Charles L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CREMOPHOR; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL;

ANAPHYLAXIS; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; DATA BASE; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INFORMATION; JAPAN; LUNG CANCER; MEDICAL RESEARCH; OVARY CANCER; PROPHYLAXIS; SHORT SURVEY; UNITED STATES;

EID: 63149109202     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70224-8     Document Type: Short Survey

References (12)

1. Zanotti KM, Markman M. Prevention and management of antineoplastic- induced hypersensitivity reactions. Drug Saf 2001;24:767-779.
2. Suffness M, ed. Taxol Science and Applications. Boca Raton, Fla: CRC Press, Inc; 1995.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-1598.
4. Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann Allergy Asthma Immunol 1998;80:159-163.
5. Taxol (Paclitaxel) injection [package insert.] 2000. Available at: http://www.fda.gov/ cder/foi/label/2000/20262S36LBL.PDF. Accessed February 12, 2009.
6. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-1268.
7. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005;293:2131-2140.
8. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
9. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220.
10. Committee on Identifying and Preventing Medication Errors. Washington, DC: National Academy Press; 2006.
11. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
12. Carbarns IRI, Hudson AJ, Wang R, Arnold B. Use of risk management planning to enhance safety of medicines. Int J Pharm Med 2007;21:415-426.